European Commission expands Vaxneuvance vaccine indication to include infants, children and adolescents
Merck Inc., has announced that the European Commission (EC ) has approved an expanded indication for Vaxneuvance Pneumococcal 15-valent Conjugate Vaccine) to include active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae (S. pneumoniae) in infants, children and adolescents from 6 weeks to less than 18 years of age
The approval facilitates availability of Vaxneuvance for this population in all 27 European Union (EU) Member States plus Iceland, Norway and Lichtenstein. Vaxneuvanceis also indicated in the EU for active immunization for the prevention of invasive disease and pneumonia caused by S. pneumoniae in individuals 18 years of age and older. The use of Vaxneuvance in the EU should be in accordance with official recommendations.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins